Fyodor Biotechnologies is a privately held, socially responsible company focused on the research, development and manufacture of innovative diagnostic and biopharmaceutical products, first targeted to large emerging economies in Africa, Asia and South America. The company’s flagship product, the Urine Malaria Test (UMT), is the first and only non-blood test that tells if a fever is due to malaria, using just a few drops of urine.
Fyodor reported five presentations or peer-reviewed journal publications resulting from this MIPS project. Seven students were involved.
In June, 2011, Fyodor was awarded a Small Business Innovation Research (SBIR) Phase I grant for $150,000 to progress the development of its innovative Urine Malaria Test (UMT) technology. In August, 2012, the company received another Small Business Innovation Research (SBIR) Phase I grant for $150,000 to develop a novel recombinant antibody to be used in a urine-based test for the point-of-need detection of Leptospirosis.
In October, 2012, Fyodor was awarded a Small Business Innovation Research (SBIR) Phase 2 grant for $476,000 to support the company’s effort to develop and validate a broad-based, non-invasive, single-step Urine Malaria Test (UMT Broad) for the clinical diagnosis of both Plasmodium falciparum (Pf) and P. vivax (Pv) malaria, which together account for over 98% of all malaria cases worldwide.
In September, 2013, Fyodor received a Small Business Innovation Research (SBIR) Phase 2 grant for $729,000 funding to accelerate the company’s effort to develop and validate a non-invasive, multi-disease, urine-based diagnostic test for Acute Febrile Illness (AFI), enabling the differential clinical diagnosis of leading global health diseases like malaria, typhoid, dengue, and leptospirosis from a single urine specimen in patients with fever.
The MIPS project has facilitated our consolidation of projects and allowed for the leveraging of additional funding.
